drugset / Trial / NCT05281510

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

NCT05281510

Phase 2 Completed 20 enrolled Gilead Sciences
NaSingle-groupOpen-labelTreatment

Summary

The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).

Timeline

Start
2022-06-09
Primary completion
2025-01-16
Completion
2025-01-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CAP256V2LS Unknown 20 mg/kg Intravenous
Subject VRC07-523LS Monoclonal antibody 20 mg/kg Intravenous
Subject Vesatolimod Small molecule 6 mg Oral
Subject Vesatolimod Small molecule 8 mg Oral